argenx NV ADR (ARGX)vsPropanc Biopharma, Inc. Common Stock (PPCB)
ARGX
argenx NV ADR
$663.93
-3.01%
HEALTHCARE · Cap: $43.52B
PPCB
Propanc Biopharma, Inc. Common Stock
$0.12
+1.45%
HEALTHCARE · Cap: $1.86M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
PPCB
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-527.8%
Fair Value
$132.94
Current Price
$663.93
$530.99 premium
Margin of Safety
N/A
Fair Value
$354.35
Current Price
$0.12
$354.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 30 of every $100 in revenue as profit
Revenue surging 74.6% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 28.1%
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 32.0%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.4% and operating margin at 28.1%. Revenue growth of 74.6% demonstrates continued momentum.
Bull Case : PPCB
The strongest argument for PPCB centers on Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : PPCB
The primary concerns for PPCB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while PPCB is a value play — different risk/reward profiles.
PPCB carries more volatility with a beta of 3.48 — expect wider price swings.
ARGX is growing revenue faster at 74.6% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 26/100), backed by strong 30.4% margins and 74.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Propanc Biopharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?